Vamorolone: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany), NICE (England) and SMC (Scotland) recommended or restricted vamorolone, while AOTMIT (Poland) and DMC (Denmark) did not recommend it.
The record spans 3.2 years, opening at AWMSG (Wales) on 23 Mar 2023 and running to 26 May 2026.
CIPM (Spain) changed its position: not recommended on 19 Jun 2025, recommended by 25 Feb 2026, after a resubmission.
No assessment is on file from HAS (France), PBAC (Australia), PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 11 of 11 records date from 2023 or later.
3 distinct indication wordings are recorded for vamorolone by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess vamorolone, on 23 Mar 2023; AIFA (Italy) did not open a file until 26 May 2026 — a wide spread of 3.2 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 5 of 11 dated records fall in 2026 alone.
CIPM (Spain) is the only agency to have returned to vamorolone, recording 4 separate entries.
8 of the 18 agencies in this archive hold a record for vamorolone.
The full ledger for vamorolone reads 5 not recommended, 2 recommended, 2 restricted and 1 no benefit, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| DMC (Denmark) | 25 Mar 2026 | Behandling af Duchennes muskeldystrofi (DMD) hos patienter i alderen 4 og derover | Ikke anbefalet, revurderes | source |
| CIPM (Spain) | 25 Feb 2026 | LABORATORIO MEDICAMENTO FORMATO CN Precio € Criterios para la financiación SANTHERA PHARMACEUTICALS (SPAIN) S.L. AGAMREE… | financed by the SNS, on appeal | source |
| AOTMIT (Poland) | 24 Feb 2026 | programu lekowego „Leczenie chorych z dystrofią mięśniową Duchenne’a (DMD) (ICD-10: G71.0) | not recommended | source |
| NICE (England) | 16 Jan 2025 | NICE TA1031 | recommended (optimised) | source |
| SMC (Scotland) | 13 Jan 2025 | For the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older. | accepted | source |
6 further decisions for vamorolone, across 4 agencies, are not shown here. They include the most recent record on file, 26 May 2026 from AIFA (Italy); its outcome is in the subscriber dataset. They link to 6 further source documents.
Related molecules
- hydrocortisone — same ATC class H02A — Systemic corticosteroids
- deflazacort — same ATC class H02A — Systemic corticosteroids
- fludrocortisone — same ATC class H02A — Systemic corticosteroids
- cabotegravir — also decided by AIFA in 2026Q2
- vutrisiran — also decided by AIFA in 2026Q2
- ciltacabtagene autoleucel — also decided by AIFA in 2026Q2
Coverage: 11 decisions for vamorolone from 8 agencies, 2023 to 2026. Data to 7 Sep 2026. ATC class H02A — Systemic corticosteroids. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.